ライフサイエンスコーパス: very late

1 ity to some viral proteins was detected only very late.

2 th GVHD in that the onset of her disease was very late.

3 to three temporal classes: early, late, and very late.

4 s, with the majority (92%) occurring late or very late.

5 The very late-acting factor CHMP1 is not recruited unless th

6 est whether natalizumab, an antibody against very late activating antigen (VLA)-4, interferes with ce

7 of eosinophils into the lung is dependent on very late activating antigen-4 (VLA-4) expression.

8 ar cell adhesion molecule-1, VCAM-1), CD49d (very late activating antigen-4, VLA-4), and/or MUC-1 on

9 a6 in the laminin-specific integrin receptor very late activation Ag (VLA)-6 (alpha6beta1).

10 of inflammatory cells, reduced expression of very late activation Ag-4, lymphocyte function-associate

11 Combined treatments of Ptx with anti-very late activation antigen (anti-VLA-4), uncovered pot

12 ent study, we investigated the importance of very late activation antigen (VLA)-4 in the early phases

13 ne the effects of sVCAM-1 on and the role of very late activation antigen 4 (VLA-4) in peripheral blo

14 and integrins on Tck cells, including CXCR4, very late activation antigen 4 (VLA-4), and lymphocyte f

15 sing TNFalpha, interleukin-1beta (IL-1beta), very late activation antigen 4 (VLA-4), vascular cell ad

16 The VCAM-1/very late activation antigen 4 adhesive system criticall

17 In turn, inflammatory cells expressing very late activation antigen-4 (VLA-4), the leukocyte li

18 rovessel endothelium via interaction between very late activation antigen-4 (VLA4) expressed on sickl

19 revious studies have shown that alpha4beta1 (very late activation antigen-4 [VLA-4]) and vascular cel

20 Minimal levels of very late activation antigen-4(+) (VLA4(+)) erythrocytes

21 aive T-cell marker, and CD29, members of the very late activation family.

22 IL233 administration either before, late or very late after renal injury can restore kidney structur

23 Mac-1 and very late Ag 5 and enhancement of very late Ag 3-mediated migration.

24 Projections formed independently of VCAM-1/very late Ag 4 interactions, shear, and proactive contri

25 ppression of migration mediated by Mac-1 and very late Ag 5 and enhancement of very late Ag 3-mediate

26 dendritic cells (DC), which recognize Hc via very late Ag 5.

27 and this molecule was identical with CD49b (very late Ag-2, alpha(2) integrin).

28 Engagement of very late Ag-4 (integrin alpha(4)beta(1)) by ligands suc

29 ndent rolling was blocked completely by anti-very late Ag-4 (VLA-4) Abs.

30 plaque, but the mechanism of CD11c/CD18 and very late Ag-4 (VLA-4) activation and cooperation in she

31 mediated, whereas beta2 integrin and VCAM-1/very late Ag-4 (VLA-4) interactions promoted static adhe

32 rming membrane ruffles and showing increased very late Ag-4 (VLA-4)-mediated adhesion to VCAM-1-expre

33 ), a high affinity peptidomimetic ligand for very late Ag-4 (VLA-4; also called integrin alpha4beta1)

34 e diseases because it binds to the integrins very late Ag-4 and alpha(4)beta(7) on lymphocytes and mo

35 eraction of VCAM-1 and its integrin receptor very late Ag-4 is believed to be critically involved in

36 rphostin AG490 are less adhesive on purified very late Ag-4 ligands compared with adhesion of leukocy

37 retion was inhibited by the addition of anti-very late Ag-4 to plasma cell/stromal cell cocultures in

38 Furthermore, cross-linking of CD49d/CD29 (very late Ag-4) on the surface of B cells rescued them f

39 Anti-VLA-4 (very late Ag-4) treatment prevented lung eosinophilia an

40 ized Hc yeasts via the fibronectin receptor, very late Ag-5, and not via CD18 receptors.

41 with manifestation from as early as birth to very late age of onset in life.

42 However, recent studies have found that at very late ages, the genetic variance components decline.

43 mRNA followed a slower time course, peaking very late and continuing expression even after the AOM w

44 r processes insinuate between glomeruli only very late and then form only a sparse, open network arou

45 bnAbs appear very late, and patients are typically not protected by t

46 otif that has homology to the alpha-chain of very late antigen (a known ligand for VCAM-1), was shown

47 The human integrin very late antigen (VLA)-2 (CD49b/CD29) mediates interact

48 Despite the higher level of very late antigen (VLA)-2, VLA-4, and VLA-5 on Sca-1(+)c

49 eceptors on Tc1 and Tc2 cells, we found that very late antigen (VLA)-4 (a heterodimer of CD49d and CD

50 sp (RGD) sensitive and partially mediated by very late antigen (VLA)-4 and VLA-5 but not alpha(v) or

51 The transient regulation of very late antigen (VLA)-4 avidity by CC chemokines may p

52 This study tested the hypothesis that very late antigen (VLA)-4 mediates CD18-independent neut

53 lar endothelial growth factor (VEGF)-induced very late antigen (VLA)-4.

54 n to be important in hematopoiesis, CD44 and very late antigen (VLA)-4.

55 s subset depends on the alpha4beta1 integrin very late antigen (VLA)-4.

56 adhesion/transmigration, upregulates preDC2 very late antigen (VLA)-5, and protects preDC2s from tum

57 ing that stem cells may express the integrin very late antigen (VLA)-5.

58 In this study, we investigated whether very late antigen (VLA)4 and VLA-6 integrins, which play

59 These findings establish human very late antigen 2 transgenic mice as a model for echov

60 Production of human integrin very late antigen 2, a receptor for echovirus type 1, in

61 ated antigen 1 (LFA-1) (alpha(L)beta(2)) and very late antigen 4 (VLA-4) (alpha(4)beta(1)).

62 Very late antigen 4 (VLA-4) and CD11/CD18 integrins medi

63 tes matrix metalloproteinase-9 secretion and very late antigen 4 (VLA-4)-mediated adhesion to vascula

64 e function-associated antigen 1 (LFA-1), and very late antigen 4 (VLA-4).

65 f chemokine receptor (CCR2) and the integrin Very Late Antigen 4 (VLA-4).

66 Anti-very late antigen 4 (VLA-4; on neutrophils) inhibited ad

67 ting of the chemokine receptor CXCR2 and the very late antigen 4 (VLA4) integrin.

68 To provide further insights into the anti-very late antigen 4 (VLA4)/anti-vascular cell adhesion m

69 e detected the active conformational form of very late antigen 4 after stimulation with a peptide mim

70 s of beta1 phosphorylation and a decrease in very late antigen 4 binding to its ligand vascular cell

71 ular signature, which includes expression of very late antigen 4 in peripheral blood, was also enrich

72 r by chemokines leads to the inactivation of very late antigen 4.

73 investigated the role of adhesion molecules (very late antigen [VLA]-4 [ alpha 4 beta 1 integrin] and

74 odies (MoAbs) enhanced integrin alpha4beta1 (very late antigen [VLA]-4) and alpha5 beta1 (VLA-5)-depe

75 The alpha1beta1 integrin, very late antigen-1 (VLA-1), is a collagen receptor expr

76 thelial growth factor receptor-3) and VLA-1 (very late antigen-1) promotes high-risk transplant survi

77 AQC2 to the alpha1 chain of human and sheep very late antigen-1, given 30 minutes before challenge,

78 on, but an increase in p150,95 (CD11c/CD18), very late antigen-1, or ICAM-1 expression was not observ

79 The integrin alpha1beta1 (very late antigen-1; CD49a/CD29) is a major adhesion rec

80 eater glycoprotein (GP) IIb/IIIa (p = 0.04), very late antigen-2 (p = 0.04) and platelet/endothelial

81 The leukocyte integrin very late antigen-4 (alpha(4)beta(1), CD49d/CD29) is an

82 The leukocyte integrin very late antigen-4 (VLA-4) (alpha 4 beta 1, CD49d/CD29)

83 hocytes that expressed low or high levels of very late antigen-4 (VLA-4) and non-antigen-specific act

84 Extremely potent very late antigen-4 (VLA-4) antagonists with picomolar,

85 nction-associated antigen (LFA-1) and VCAM-1/very late antigen-4 (VLA-4) at select time points compar

86 rsor cells were transiently transfected with very late antigen-4 (VLA-4) binding to vascular cell adh

87 Further, B cell-restricted very late antigen-4 (VLA-4) deficiency abrogated EAE dep

88 later, GVHD-associated increase in CD25 and very late antigen-4 (VLA-4) expression on donor T cells

89 lar endothelial growth factor receptor-1 and very late antigen-4 (VLA-4) have been shown to arrive at

90 esent study was to determine the role of the very late antigen-4 (VLA-4) integrin/ligand interaction

91 te function-associated antigen-1 (LFA-1) and very late antigen-4 (VLA-4) on adhesion of influenza hem

92 The expression of very late antigen-4 (VLA-4) on the surface of MBP-primed

93 scular cell adhesion molecule 1 (VCAM-1) and very late antigen-4 (VLA-4) played an integral role in t

94 Interaction of very late antigen-4 (VLA-4) with its ligand vascular cel

95 ion, we show that MBP-primed T cells express very late antigen-4 (VLA-4), and functional blocking ant

96 the adhesion molecules CD11a, CD11b, CD11c, very late antigen-4 (VLA-4), and L-selectin, as assessed

97 we evaluated the role of targeted imaging of very late antigen-4 (VLA-4), as a key integrin mediating

98 The alpha(4)beta(1)-integrin (very late antigen-4 (VLA-4), CD49d/CD29) is an adhesion

99 portance of VCAM-1, and its leukocyte ligand very late antigen-4 (VLA-4), in such leukocyte migration

100 Natalizumab, which binds very late antigen-4 (VLA-4), is a potent therapy for mul

101 he affinity of the alpha(4)beta(1) integrin, very late antigen-4 (VLA-4), measured with an LDV-contai

102 lasts within the bone marrow is adhesion via very late antigen-4 (VLA-4), the alpha(4)beta(1) integri

103 D49d), in complex with integrin beta1, forms very late antigen-4 (VLA-4), which interacts with vascul

104 cular cell adhesion molecule-1 (VCAM-1)- and very late antigen-4 (VLA-4)-mediated localization of CXC

105 and human monoblastoid U937 cells expressing Very Late Antigen-4 (VLA-4).

106 ascular cell adhesion molecule-1 (VCAM-1) or very late antigen-4 (VLA-4).

107 une cells from patients under long-term anti-very late antigen-4 (VLA-4)/natalizumab therapy (LTNT) a

108 skin fibroblasts, making it unlikely that a very late antigen-4 (VLA-4)/VCAM-1 interaction is requir

109 ion of one of the major leukocyte integrins, very late antigen-4 (VLA-4, CD49d/CD29).

110 Melanocortin-1 receptor (MC1R) and very late antigen-4 (VLA-4, integrin alpha(4)beta(1)) ar

111 duced by IL-3 in a dose-dependent manner via very late antigen-4 (VLA-4; alpha4beta1 integrins) and V

112 Very late antigen-4 (VLA-4; also called integrin alpha4b

113 ascular cell adhesion molecule-1 (VCAM1) and very late antigen-4 (VLA4) using monoclonal antibodies.

114 cule antagonist, compound A, to nonactivated very late antigen-4 (VLA4) was examined in lung inflamma

115 BL1(+) progenitors had similar expression of very late antigen-4 (VLA4), VLA5, leukocyte functional a

116 elated protein ligand, resulting in enhanced very late antigen-4 [VLA-4] directed adhesion and motili

117 lymphocyte adhesion but partially conserved very late antigen-4 adhesiveness.

118 irway inflammation and was prevented by anti-very late antigen-4 and anti-interleukin-5 treatments, w

119 Very late antigen-4 and CD11/CD18 integrins mediated pas

120 and natalizumab (Tysabri/Antegren) targeting very late antigen-4 for the treatment of relapsing-remit

121 ncrease expression of VCAM-1, a receptor for very late antigen-4 found on many hematopoietic progenit

122 dent mechanism to increase CD11c expression, very late antigen-4 function, and integrin coclustering

123 for the integrin alpha4beta1 (also known as very late antigen-4 or VLA-4).

124 te function-associated antigen-1) and VLA-4 (very late antigen-4) is essential for T-cell trafficking

125 (NPCs) expresses VLA4 (integrin alpha4beta1, very late antigen-4) that facilitates NPC entry into the

126 tide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1.

127 The antigen alpha4beta1 (very late antigen-4, VLA-4) plays an important role in t

128 al cells, and mild expression of its ligand, very late antigen-4, was apparent in perivascular lympho

129 imilar to, but more restricted than, current very late antigen-4-directed approaches that have signif

130 Activated T cells use very late antigen-4/alpha4beta1 integrin for capture, ro

131 The optimization and validation of the very late antigen-4/vascular cell adhesion molecule-1 as

132 nocyte chemoattractant protein-1) and VLA-4 (very-late antigen-4).

133 , a ligand for the alpha(4)beta(1) integrin, very-late-antigen-4 (VLA-4 or CD49d).

134 Very-late-antigen-4 (VLA-4, alpha4beta1 integrin, CD49d/

135 ve been associated with an increased risk of very late (beyond 1 year) stent thrombosis.

136 tality was markedly increased after late and very late BMS thrombosis, particularly during the first

137 tructure and function, potentially improving very late clinical outcomes.

138 n beta2 expression in bipolar cells occurred very late, coinciding with synaptogenesis in the inner p

139 The C. elegans nuclear envelope disassembles very late compared with vertebrates and Drosophila.

140 omotic hemorrhage of the donor duodenum as a very late complication, >10 years after transplantation

141 lopidogrel treatment >12 months may decrease very late death or MI only in patients with DM receiving

142 Very late definite or probable stent thrombosis occurred

143 The risks of early/late (up to 1 year) and very late definite ST (after 1 year) were estimated.

144 95% CI: 0.07 to 0.46), with a lower risk of very late definite stent thrombosis in the EES group (0.

145 patients, due largely due to a lower risk of very late definite stent thrombosis.

146 The threshold excess risk of very late DES thrombosis compared with BMS, above which

147 ly ascribed to G2, overlaps extensively with very late DNA replication.

148 e enzyme-bound DNA substrate, and then, only very late during the reaction trajectory do strong speci

149 The p7/p1 mutation appeared very late during the selection process and was strongly

150 lones containing protease mutations observed very late during the selection process were constructed

151 duced during erythropoiesis, and abundant in very late erythroblasts.

152 events (1.6%), 32 late events (1.0%), and 33 very late events (1.1%).

153 The pathogenesis of these very late events is likely related to the permanent pres

154 zinc finger domain contributed primarily to very late events.

155 Very late expression factor 1 (VLF-1) of Autographa cali

156 Very late factor 1 (VLF-1) of Autographa californica mul

157 The product of the vlf-1 (very late factor 1) gene is required for expression of v

158 Along with very late flowering, these transgenic plants produced a

159 rring Arabidopsis (Arabidopsis thaliana) are very late flowering, unless flowering is promoted by a p

160 ngly up-regulated by FRI-Sf2, resulting in a very late-flowering phenotype.

161 ed by cAMP indicate that the block occurs in very late G1.

162 yrosine recombinase and is required for both very late gene expression and budded virus production.

163 factor 1) gene is required for expression of very late genes during the final phase of infection.

164 f transcripts from selected early, late, and very late genes showed that late and very late transcrip

165 KO/GUS showed that transcription of late and very late genes was lower at later times posttransfectio

166 tailbud contains multipotent cells that make very late germ-layer decisions.

167 Risk of late (30 days to 1 year) and very late (>1 year) BMS thrombosis was increased among p

168 ly (<30 days), late (30 days to 1 year), and very late (>1 year) periods (pinteraction = 0.49).

169 In late (>1 month) and very late (>1 year) ScT (respectively, 5 and 2 cases), 5

170 Very-late (>1-year) stent-related MACE have not been wel

171 Very late IA (> 6 months after transplantation) was asso

172 unctional abnormality (ataxia) develops only very late in alpha-TTP-KO mice in spite of the severe al

173 ot show any enrichment of Mi-2/NuRD proteins very late in culture.

174 e when breaks were made either very early or very late in development, but was much more frequent in

175 sequentially, with some being expressed only very late in development.

176 creatic islets; it is usually diagnosed only very late in disease progression, after the critical aut

177 rski images); and finally, we analyze clones very late in embryonic development, which reveals novel

178 dependent antiviral gene expression occurred very late in infection.

179 r as T prolymphocytic leukemias, which occur very late in life, or as T chronic lymphocytic leukemias

180 novel including S/D10, a cDNA only expressed very late in pollen development and highly up-regulated

181 ing the IS1112C male-sterile cytoplasm occur very late in pollen maturation.

182 ctions in (5me)C content in the genome occur very late in prostate cancer progression, appearing at a

183 trations of LINE-1 elements to be replicated very late in S phase.

184 In P. falciparum, MyoB is synthesized very late in schizogony/merogony, and its location in me

185 Q into high-molecular-mass forms occurs only very late in sporulation, after mother cell lysis.

186 ospice, and those who enroll generally do so very late in the course of their illness.

187 und compartments in the larval brain, appear very late in the embryonic neuropile, clearly after the

188 Finally, Sec2p is dephosphorylated very late in the exocytic reaction to facilitate recycli

189 species damage, a feature not observed until very late in the pathology of the CIV model.

190 Separation of the sites of chemistry until very late in the splicing pathway may be crucial for pre

191 A1, also protected glycogen stores, but only very late in the stationary phase.

192 ed that the side-chain epoxide be introduced very late in the synthesis, owing to the ease with which

193 integrin (CD103) expression is up-regulated very late in thymic development on a subset of CD8(+)/CD

194 thrombosis, which is relevant to reports of very late in-stent thrombosis at altitude.

195 on traverse of G1 or S, but stalled cells in very late interphase.

196 Very late LAVA (>100 ms after QRS complex) were almost e

197 Very-late MACE (a composite of cardiac death, myocardial

198 Between years 1 and 5, very-late MACE occurred in 9.4% of patients (including 2

199 Very-late MACE occurred in 9.7%, 11.0%, and 8.3% of pati

200 the domain has generally been restricted to very late Mesoproterozoic and Neoproterozoic successions

201 ifornica nuclear polyhedrosis virus late and very late mRNAs are transcribed by an RNA polymerase con

202 , in part, responsible for resistance to the very late onset disease.

203 That allele may contribute to very late onset form of Alzheimer disease when we are ag

204 ep phase disorder (DSPD), characterized by a very late onset of sleep.

205 lated to demographic data (non-white origin, very late onset), clinical features (limited recovery fr

206 GS differs notably from CVID and B(-) CVID: very late onset, no familial cases, and absence of lymph

207 e familial characteristics of high-incidence very late-onset AD (VLOAD, defined here as AD with onset

208 Very late-onset AD may be a good target for investigatin

209 llele-bearing genes that are associated with very late-onset AD should target the families of nonagen

210 4 and 15q22 are linked to early-onset AD and very-late-onset AD, respectively.

211 proteins that increases susceptibility to a very-late-onset form of AD.

212 ia (illness onset after 40 years of age) and very-late-onset schizophrenia-like psychosis (onset afte

213 he positions of late-onset schizophrenia and very-late-onset schizophrenia-like psychosis.

214 izophrenia into early-onset, late-onset, and very-late-onset subtypes now should be tempered by the r

215 >12 months versus </=12 months after PCI on very late outcomes in patients with diabetes mellitus (D

216 or, implicating cAMP signaling by PDE4B in a very late phase of consolidation.

217 s a 10-kDa auxiliary protein produced in the very late phase of gene transcription by Autographa cali

218 ntial for the burst of expression during the very late phase.

219 ls, indicating progression into the late and very late phases of viral infection.

220 A polymerase stimulated transcription of the very late polyhedrin promoter but not the late 39k promo

221 Very late potentials (vLP) were defined as electrograms

222 Of all the fractionated, late, and very late potentials located in scar, only 21%, 26%, and

223 provide evidence that Rio1 associates with a very late pre-40S via its conserved C-terminal domain.

224 in-air capture motions were aborted, even at very late prey removals (<20 ms = 6 cm before expected c

225 ate and specific transcription from late and very late promoters but was not active on viral early pr

226 the burst sequences of both the polh and p10 very-late promoters.

227 In contrast, very late reactivities may signify chemotactic propertie

228 A very late recurrence (VLR) of atrial fibrillation (AF) i

229 Reliable prediction of very late recurrence of atrial fibrillation (VLRAF) occu

230 Under these conditions, dormant origins fire very late relative to other active origins.

231 /M cyclin fusion was functional for MMR at a very late-replicating region of the genome.

232 sition states for C-H oxidative addition are very late, resembling the aryl iridium hydride intermedi

233 Although only a few origins that fire in very late S phase have been identified in fission yeast,

234 This study examined whether very late scaffold thrombosis (VLScT) occurs when resorp

235 splantation experiments indicating that even very late sclerotome tissue fragments are multipotential

236 The predominant finding in late and very late ScT is peristrut low-intensity area.

237 caffold collapse was found in 1 patient with very late ScT.

238 1 days to 1 year), cumulative 1-year ST, and very late ST (1-2 years).

239 The risk of very late ST is low and comparable between n-DES and BMS

240 and larger studies will have to show whether very late ST rates will also be improved in newer DES.

241 to 2.98; p = 0.21), whereas a higher risk of very late ST was observed with o-DES compared with BMS (

242 The risk of very late ST was similar between the n-DES and BMS group

243 nd 155 (71.4%) presented with early and late/very late ST, respectively.

244 3.3%) and severe restenosis (19.1%); and for very late ST, the most common dominant finding was neoat

245 In patients presenting very late ST, uncovered stent struts were a common domin

246 BVS had a higher risk of subacute, late, and very late ST, whereas the risk of acute ST was similar.

247 BVS had a higher risk of subacute, late, and very late ST, whereas the risk of TLF and TLR was higher

248 ronic inflammation, predisposing to late and very late ST.

249 atherosclerosis and uncovered struts in late/very late ST.

250 ment is associated with an increased risk of very late ST.

251 ificantly reduced ARC definite ST, including very late ST.

252 or pancreatic cancer is often diagnosed at a very late stage at which point treatment options are min

253 -CD8 cells can block HSV-1 reactivation at a very late stage in the viral life cycle.

254 We conclude that L40 is assembled at a very late stage into pre-60 S ribosomal subunits and tha

255 ecific needs, such as water solubility, on a very late stage of the multistep synthesis are described

256 evere, sustained pulmonary hypertension in a very late stage of the Sugen 5416/hypoxia/normoxia-expos

257 entified a new function of IFITMs during the very late stage of virus replication, i.e., virion assem

258 found that most converging forks stall at a very late stage, indicating a role for additional factor

259 ides a first glimpse into the structure of a very late-stage intermediate in the lesion-extrusion pat

260 s when soil fauna are absent or litter is in very late stages of decomposition (near-humus).

261 Instead, SAP is necessary for very late stages of differentiation or, most likely, for

262 junctions and other branched species at the very late stages of mitosis.

263 in complex that can regulate EGFR traffic at very late stages of the endocytic pathway.

264 to HCC, while Ctnnb1 mutations occur only at very late stages.

265 d similar risks of late definite or probable very late stent thrombosis (RR, 1.06; 95% CI, 0.53-2.11;

266 n AMI are still feared for possible late and very late stent thrombosis (ST).

267 The pathomechanisms underlying very late stent thrombosis (VLST) after implantation of

268 indings regarding the prevalence of late and very late stent thrombosis (VLST) and the mechanisms tha

269 Thus, very late stent thrombosis (VLST) attributable to durabl

270 We sought to define what incremental risk of very late stent thrombosis (VLST) in drug-eluting stents

271 Furthermore, the contribution of very late stent thrombosis (VLST) to these events remain

272 dies on the pathophysiological mechanisms of very late stent thrombosis (VLST).

273 as been observed frequently in patients with very late stent thrombosis after drug eluting stent impl

274 arly (0-30 days), late (31 days-1 year), and very late stent thrombosis amounted to 0.6, 0.1, and 0.6

275 with EES is associated with a lower risk of very late stent thrombosis compared with early-generatio

276 n, less fibrin deposition, and less late and very late stent thrombosis compared with SES and PES in

277 Observational studies suggest higher very late stent thrombosis incidence, but the relative r

278 (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after stent

279 It is unknown whether the risk of very late stent thrombosis persists with newer-generatio

280 The incidence of very late stent thrombosis was also similar between the

281 The observed frequency of late and very late stent thrombosis was less in CoCr-EES (4%) ver

282 There was no increase in very late stent thrombosis with EES versus BMS (RR, 0.89

283 t-generation DES and BMS with no increase in very late stent thrombosis.

284 herapy due to the increased risk of late and very late stent thrombosis.

285 ue to a metal cage, and the risk of late and very late stent thrombosis.

286 Furthermore, the risk of very late stent, although substantially reduced with new

287 thrombosis (RR, 3.22; 95% CI, 1.89-5.49) and very late stent/scaffold thrombosis (>1 year; RR, 4.78;

288 te or probable stent/scaffold thrombosis and very late stent/scaffold thrombosis seems to be higher w

289 scale, individual patient data pooled study, very-late stent-related events occurred between 1 and 5

290 as to assess the frequency and predictors of very-late stent-related events or MACE by stent type.

291 able protocol for postharvest storage of the very-late Tarocco "Sant'Alfio" orange to prolong the ava

292 s, ICP27 was confined to the nucleus even at very late times after infection.

293 Interestingly, even at very late times postinfection, a mixture of multiple sma

294 te, and very late genes showed that late and very late transcription was absent in cells transfected

295 ion was apparently unaffected, both late and very late transcription were delayed in cells infected w

296 refore, we hypothesize that KN-93 prevents a very late, uncharacterized step in cyclin D/cdk4 activat

297 during virus DNA synthesis and impaired both very late viral gene expression and production of infect

298 5 increased transcription from both late and very late viral promoters.

299 , whereas its caspase (ORF073) was expressed very late, which correlated with apoptotic events leadin

300 People with glaucoma frequently present very late with advanced disease, and acceptance of and a